NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase’s pipeline includes therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington's disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.”
View Top Employees from NeuBase Therapeutics, Inc.| Website | http://www.neubasetherapeutics.com |
| Ticker | NBSE |
| Revenue | $15 million |
| Employees | 24 (24 on RocketReach) |
| Founded | 2018 |
| Address | 350 Technology Drive, Pittsburgh, Pennsylvania 15221, US |
| Phone | (989) 930-0001 |
| Technologies |
JavaScript,
HTML,
PHP
+26 more
(view full list)
|
| Industry | Pharmaceutical Manufacturing, Drug Manufacturing & Research, Biotechnology, Pharmaceuticals, Science and Engineering, Healthcare, Medical, Health Care, Therapeutics |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 32541 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 325413 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies |
Looking for a particular NeuBase Therapeutics, Inc. employee's phone or email?
NeuBase Therapeutics, Inc. Questions
The NeuBase Therapeutics, Inc. annual revenue was $15 million in 2024.
Todd Branning is the CFO of NeuBase Therapeutics, Inc..
24 people are employed at NeuBase Therapeutics, Inc..
NeuBase Therapeutics, Inc. is based in Pittsburgh, Pennsylvania.
The NAICS codes for NeuBase Therapeutics, Inc. are [32541, 54, 541, 325413, 3254, 32, 325].
The SIC codes for NeuBase Therapeutics, Inc. are [28, 283].
Top NeuBase Therapeutics, Inc. Employees
-
5+2
-
24
-
34
-
View
Jessica Balogh
Executive Assistant to Chairman and CEO at NeuBase Therapeutics, Inc.
Pittsburgh, PA, US31 -
1
-
22
Related Companies
